American Society of Clinical Oncology Genitourinary Cancers Symposium

ASCO-GU 2022

This program was supported by Bayer Inc.

asco-gu-2022

Prostate cancer conference highlights

AUDIO & VIDEO CAPSULES

Moderated by Dr. Steven Yip

This conference is available through our podcast

Abstract Summaries

Dr Sebastien Hotte (English)

Abstract 13 – Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
ASCO-GU 2022
ASCO-GU 2022
Dr Sebastien Hotte (English)
/

Watch video capsule

Abstract Summaries

Dr. Sebastien Hotte (French)

Abstract 13 – Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial

ASCO-GU 2022
ASCO-GU 2022
Dr. Sebastien Hotte (French)
/

Watch video capsule

Abstract Summaries

Dr. Lucia Nappi

Abstract 12 – Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations

ASCO-GU 2022
ASCO-GU 2022
Dr. Lucia Nappi
/

Watch video capsule

Abstract Summaries

Dr. Laurence Klotz

Abstract 11 – PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

ASCO-GU 2022
ASCO-GU 2022
Dr. Laurence Klotz
/

Watch video capsule

Abstract Summaries

Dr. Tamim Niazi

Poster 256 – Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS

ASCO-GU 2022
ASCO-GU 2022
Dr. Tamim Niazi
/

Watch video capsule

Abstract Summaries

Dr. Ramy Saleh

Abstract 10 – PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

ASCO-GU 2022
ASCO-GU 2022
Dr. Ramy Saleh
/
Rate this summary:

Watch video capsule

The opinions expressed in these capsules are those of the physicians.

The contents of this site may contain information regarding indications and/or instructions which differ from the approved use of products available in Canada. For complete information, please refer to the respective conference sessions and product monographs available through the manufacturer’s website. The safety and efficacy of some of the products described herein are still under investigation and have not received market authorization from Health Canada.

This website is intended for Canadian healthcare professionals.

MA-M_DAR-CA-0227